HEMATOLOGY

Jonathan L. Kaufman, MD, discusses current challenges and unmet needs in the treatment landscape and provides insight into potential improvements in the future of multiple myeloma.

Expert in the management of multiple myeloma Jonathan Kaufman, MD, reviews factors to consider when selecting a treatment regimen for patients with relapsed disease.

Jonathan L. Kaufman, MD, considers updates from the GRIFFIN trial, the MAIA trial, and the PEGASUS study and comments on factors to consider for daratumumab-containing induction regimens.

Key opinion leader in hematology Jonathan L. Kaufman, MD, discusses standard treatment options for newly diagnosed multiple myeloma in transplant and nontransplant treatment settings.

An expert hematologist discusses factors to consider when determining a treatment approach in newly diagnosed multiple myeloma including symptom burden, comorbidities, age, and ECOG performance status.

Jonathan L. Kaufman, MD reviews the case of a 75-year-old man with multiple myeloma by discussing the patient’s presentation, clinical workup, and initial prognosis.

A key opinion leader in hematology, Jonathan Kaufman, MD, provides insight into the case of a 75-year-old man with multiple myeloma and discusses treatment considerations, standard of care therapies, and recent clinical trial updates for the management of multiple myeloma.

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

A rolling submission of a New Drug Application has been completed for pacritinib which is seeking FDA approval as a treatment for patients with myelofibrosis who have severe thrombocytopenia.

The FDA has granted approval to the combination of isatuximab added to carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

In patients with polycythemia vera, long-term use of the histone deacetylase inhibitor givinostat may be warranted after the agent demonstrated tolerable safety and good efficacy over a 4-year period in an ongoing, multicenter, open-label, single-arm study of patients with a chronic myeloproliferative neoplasm who are positive for a JAK2 V617F mutation.

Sagar Lonial, MD, FACP, discusses the management of heavily pretreated relapsed/refractory multiple myeloma and its future.

An expert in multiple myeloma provides insight on the role of belantamab mafodotin in the treatment of heavily pretreated patients with relapsed/refractory multiple myeloma.

Principal investigator Sagar Lonial, MD, FACP, discusses the DREAMM-2 trial and relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, reviews and comments on the treatment options for patients with triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, summarizes the case of a 72-year-old man with heavily pretreated, triple-class relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.

A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.

Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.

A key opinion leader in medical oncology reviews optical and hematological toxicities of belantamab mafodotin and discusses how to mitigate adverse events.

An expert in multiple myeloma considers rationale for targeting BCMA and discusses recent FDA approval of belantamab mafodotin based on the DREAMM 2 trial.

Sagar Lonial, MD, FACP, discusses factors to consider when selecting later lines of therapy for patients with triple-class refractory multiple myeloma (MM).

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.

Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.

The FDA has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

In relapsed and untreated patients with mantle cell lymphoma, the combination of obinutuzumab, ibrutinib, and venetoclax achieved molecular response rates and was found to be well tolerated, results from the phase 1/2 OAsIs trial demonstrate.

Newer therapies being explored to address treatment gaps in acute graft-versus-host disease (GVHD), and advice to community oncologists/hematologists who manage cases of GVHD and/or care for patients who receive allotransplants.

The rationale for treating steroid-refractory acute graft-versus-host disease with ruxolitinib, a JAK inhibitor, and recommendations for monitoring and managing treatment-related adverse events.

Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.

Considerations for assessing response to steroid therapy as initial therapy for acute graft-versus-host disease and factors that impact next-line therapy, when necessary.